diphenylamine has been researched along with Carcinoma, Ductal, Pancreatic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beer, AJ; Braren, R; Esposito, I; Fingerle, A; Gupta, A; Heid, I; Sengkwawoh-Lueong, S; Siveke, JT; Steiger, K; Teichmann, N; Trajkovic-Arsic, M; Wenzel, P; Wörner, C | 1 |
| Burmi, RS; Gabra, H; Maginn, EN; Stronach, EA; Wasan, HS | 1 |
2 other study(ies) available for diphenylamine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diffusion Magnetic Resonance Imaging; Diphenylamine; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; MAP Kinase Kinase Kinases; Mice; Neoadjuvant Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2017 |
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Morpholines; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; TOR Serine-Threonine Kinases; Triazines | 2019 |